Konstantinos Malandris, Stylianos Papandreou, Despoina Vasilakou, Panagiota Kakotrichi, Anna Sarakapina, Georgios Kalopitas, Thomas Karagiannis, Olga Giouleme, Eleni Bekiari, Aris Liakos, Fotini Iatridi, Paschalis Paschos, Emmanouil Sinakos, Apostolos Tsapas
BACKGROUND AND AIM: Several agents are under investigation for nonalcoholic fatty liver disease (NAFLD). We assessed the comparative efficacy of pharmacologic interventions for patients with NAFLD focusing on magnetic resonance imaging (MRI) biomarkers. METHODS: We searched Medline, Embase, and CENTRAL. We included randomized controlled trials of more than 12 weeks of intervention that recruited patients with biopsy-confirmed or MRI-confirmed NAFLD and assessed the efficacy of interventions on liver fat content (LFC) and fibrosis by means of MRI...
April 16, 2024: Journal of Gastroenterology and Hepatology